

Cloud Services for Ahmadu Bello University

Ahmadu Bello University is desirous of the implementation of best practice in the management of official documents and collaborations amongst faculty, students and other administrative units. It is in that light that the University established a Data Centre with adequate servers configured to have virtual machines using Proxmox. All the applications used in the University are hosted in the Data Centre. There is a provision of power backup to assure availability and a three 1GBPS Internet bandwidth from three different providers all on BGP (Boarder Gateway Protocol). The University also acquired Microsoft 365 A1 for Education license. Although the license is free for some cloud-based services in the Office 365 suite, faculty members and students have one terabytes OneDrive cloud storage. Similarly, official documents are available to authorised users via Microsoft Teams and SharePoint.

The University is working to migrate the email services to Microsoft Exchange, which is part of the Microsoft 365 A1 for education package.

[EXTERNAL] Re: M365 Commercial Purchase - TrackingID#2307240050004524 6 messages

From: "Rechelle" <support@mail.support.microsoft.com>
To: "msumar" <msumar@abu.edu.ng>
Sent: Wednesday, July 26, 2023 5:36:21 PM
Subject: M365 Commercial Purchase - TrackingID#2307240050004524

Dear Shuaibu,

Thank you for your email.

I have gone through the information you have provided, and I am pleased to inform you that your account has been successfully tagged as EDU and you are now approved to purchase the **Microsoft 365 A5** subscription.

Kindly log out of the **Microsoft 365** admin center, close your web browser instance, re-open the browser, and log in again. In this way your admin will restart, and the EDU offers should appear.

After this you can go ahead and navigate to the Purchase section to purchase **Microsoft 365 A5** subscription.



For your future reference, here is a support link on how to: [Try or buy Microsoft 365](#)

Is there anything else I can help you with aside from this?

Let me know if you have any questions by replying to this email - I am available between 11:00 am - 8 pm EST, [Monday to Friday](#).

Sincerely,
Rechelle P. Capuno
Microsoft 365 Subscription and Billing for Business
Email: cvg_mdc_recap_css@office365support.com | v-rcapuno@microsoft.com | Working Hours: 11:00 AM EST - 8:00 PM EST
Team Lead: Lester John Bella | Email: v-2leb@microsoft.com
Local Support Number: 1-800-865-9408

The login is www.login.microsoft.com




So far, more than one thousand five hundred faculty and students have been created on the Microsoft 365 platform.

INSTITUTIONAL DATA AGGREGATED IN CLOUD


1: Acquisition of Data Analytics

Microsoft has offered the Microsoft 365 A1 for Education license to Ahmadu Bello University, which consists of several applications in the suite: Word, Excel, PowerPoint, Power BI, SharePoint, Teams, Forms and others. Faculty members and students were given a combined 60,000 licenses. So far, over 5,000 accounts have been created on Microsoft 365.

Below is the email conversation with a Microsoft personnel conveying the approval of the license.




Microsoft 365 Account Creation Window





2: Training in Data Collection - Microsoft Forms and the use of Human Resources, Staff and Students' Portals

The training was conducted for some selected staff from academic departments, the Registry and Management Information System unit of the University.

Some training photos





3: Data Repository: Data Repository for staff and students have been created. Access is provided to the dumped files in text formats (mostly CSV) or using data access methods such as ODBC, DSN, etc.

4: Training on Data Analytics – Microsoft Power BI

The training in milestone 2 has been extended to include Microsoft Power BI for registration officers at faculties, MIS staff and some Registry staff. Data sources from the repository were used in the training, where participants were given read-only access to develop their data sources in Power BI. About 300 personnel of the university received training in a span of three days.

5: Enhancement of Data Security

Cybersecurity experts were encouraged to audit the security of our IT infrastructure and services. A report was submitted, and measures proposed were implemented. The report is attached to this report.

6: Decision makers Training

Deans, directors, head of departments and members of the University Management received training on access to information and visualized information.

7. Conclusion

It is important to note that N10 million Naira has been made available for the following:

- Network and Security Improvement
- Cloud Storage
- Data Analytics Tool license

Since the University obtained Microsoft 365 A1 for Education from Microsoft, which is a free service, the provision of Data Analytics tool was added to the Network improvement. Similarly, the N1 million for cloud storage was used in Network improvement since the power in the University's Data Centre became stabilized. That means, about N10m has been spent in network improvements across faculties and hostels. That has significantly improved access to the University's infrastructure and information resources. Faculties that have been disconnected from the university's network due to faulty network equipment had their connectivity restored.

The accompanying Excel spreadsheet summarises where installations of network have been made.

Research and Innovation Unit website <https://abu.edu.ng/research-and-innovation-unit/>

POLICY DOCUMENTS

Login

Admissions

Ethics Form ▾

OpenAIR

Alumni

Programmes

CONTACT



Home

About Us ▾

News ▾

Academics ▾

Institutes & Centers ▾

Library

Journals

Resources ▾

[Home](#) » [Research and Innovation Unit](#)

RESEARCH AND INNOVATION UNIT, DIRECTORATE OF ACADEMIC PLANNING AND MONITORING, AHMADU BELLO UNIVERSITY, ZARIA



Professor Maina Joy

Deputy Director

WELCOME NOTE FROM THE DEPUTY DIRECTOR

I welcome all staff and students of our great institution to join in the huge but critical task of research and innovation as one of the most fundamental and cardinal mandates of any institution of learning if we are to improve teaching and learning that address societal problems and needs. This is a core responsibility of any academic and we must strive to fulfil expectations of our society vested in our calling and noble profession.

About the Deputy Director

Mandates of the Unit

Achievements

PERSONAL DETAILS

Title: Professor

Surname: Maina

First name: Joy

Highest Educational Qualification: PhD

Rank: Professor

Telephone No: 0909 0271 277

Official E-mail: jjmaina@abu.edu.ng

Personal E-mail: joyamina16@gmail.com

Office Address: Room 413, Senate Building, Samaru Main Campus, Ahmadu Bello University, Zaria

Unit: Research and Innovation Unit, Directorate of Academic Planning and Monitoring, Ahmadu Bello University, Zaria

Schedule of Duties: Management of Research and Innovation activities across all sectors of the university, Staff trainings as well as managing the Ahmadu Bello University TETFund Research Desk Office



[About the Deputy Director](#)**[Mandates of the Unit](#)**[Achievements](#)**MANDATES OF THE UNIT**

1. Coordinate the implementation of the University's Research Policy in collaboration with Departments, Units and Centres as well as with the School of Postgraduate Studies;
2. Provide information, collate, administer, manage and coordinate research activities across the University;
3. Facilitate sponsorship, monitoring and evaluation of research processes and progress in the University;
4. Promote and publicize research findings and activities of the University;
5. Stimulate innovations and facilitate the promotion of Intellectual Property Rights and Technology Transfer (IPTT);
6. Train staff and postgraduate students on research related matters, including technical report writing, academic and grant writing, oral presentation of research output, ethical procedures etcetera;
7. Serve as Secretariat to the University Ethics Committee, with its 2 sub-committees on Human Participants and Animal Use and Care whose members are to be drawn from relevant units of the University;
8. Inform and seek approval from the University Board of Research regarding its activities and plans for onward submission to the University Senate.




ACHIEVEMENTS

1. Accessing and utilising the TETFund Journal Intervention line since 2012 for the Nigerian Journal of Engineering
2. Organising the smooth transition of submissions for TETFund Intervention lines via the Fund's online platform
3. Organisation of Grant Proposal Writing Workshops to improve the University's grant winning base
4. Successful monitoring and management of NRF Grants (2019-2022) won by staff of the University.
5. Organising a Curriculum Review and Evaluation Train-the-Trainer Workshop across all 106 departments of the University in conjunction with Quality Assurance Unit of the Directorate and the School of Postgraduate Studies
6. Organising Faculty-Wide Research and Grant trainings across Faculties in the University, commencing with Faculties of Basic Clinical Sciences and Social Sciences
7. Publication of the Ahmadu Bello University Research Newsletter
8. Maintaining up to date records of grants won in the University as well publicizing same via the University website grants@abu.edu.ng
9. Successful review and publication of the Research Policy document on the University website
10. Managing 80 Institution Based (TETFund) Research grants from 2017 to date



RESEARCH AND INNOVATION UNIT OFFICES at DIRECTORATE OF ACADEMIC PLANNING AND MONITORING, 4TH FLOOR, SENATE BUILDING, AHMADU BELLO UNIVERSITY Pictures show equipment currently in use

















- ABU Mail
- ABU Moodle
- Staff Portal
- Student Portal
- MIT Open Courseware
- OpenAIR
- ICT Centre
- Open Educational Resources
- Sasakawa

Search

SEARCH



Recent Posts

[NBTE team arrives at ABU's Samaru College of Agriculture for accreditation](#)

[Approved New Registration Charges for Undergraduate Students](#)



INSIDE THIS ISSUE

- Depressive Genetics In Africa (DEPGENAFRICA)- The Genetics Of Major Depressive Disorder In African Populations: Improving Generalizability, Causal Inferences And Reducing Disparities. **PG 01**
- ACENTDFB-supported Postgraduate Students Of Biochemistry Department International Research Awards. **PG 03**
- Nigerian LNG Limited Prize Award For Science 2022. **PG 04**
- African Studies (ASR) Prize For The Best Africa-based Doctoral Dissertation In 2022: A Contextual Analysis Of Sufi Saint Paintings In Kano, Nigeria. **PG 04**
- Publications from Soil Mechanics And Geo-environmental Engineering Research Group, Department Of Civil Engineering. **PG 06**
- Publications from Materials Physics Research Group Department Of Physics. **PG 07**
- Publications from Physical Chemistry Research Group, Department Of Chemistry. **PG 08**
- Patent Awarded. **PG 11**
- Grants. **PG 11**
- Grants, Fellowships And Funding Opportunities. **PG 13**
- ERC Funding And Fellowships **PG 25**

From the Vice-Chancellor's Desk



I am pleased to introduce the 1st edition of our 2023 Ahmadu Bello University Research Newsletter. This issue showcases positive outcomes of research related activities from various research units and groups across the University in form of research briefs, publications, awards, prizes and grants won by staff since the maiden edition of the newsletter was published in 2022.

Attracting funds through grants, fellowships and collaboration is a fundamental aspect of research. It is also critical for the visibility, growth and expansion of the University and its impact on local, regional and national development. The current edition also presents several funding avenues open to researchers to explore and maximise towards securing grants and fellowships. It is my hope that the reports and opportunities contained in this newsletter will motivate members of the University community to utilise available opportunities for research grants, awards, prizes as well as funding.

Thank you.

Professor Kabiru Bala
Vice-Chancellor

DEPRESSIVE GENETICS IN AFRICA (DepGenAfrica)- THE GENETICS OF MAJOR DEPRESSIVE DISORDER IN AFRICAN POPULATIONS: IMPROVING GENERALIZABILITY, CAUSAL INFERENCES AND REDUCING DISPARITIES

Professor Taiwo Lateef Sheikh, Team Lead (Nigeria), Department of Psychiatry

The aim of the project, funded by Wellcome Trust in the United Kingdom, is to further identify the genetic architecture of depression in individuals of African ancestries, and to use this information to identify disease mechanisms, improve predictive analytics and thereby address growing health inequalities. The study hopes to identify the genetic architecture of depression in five thousand

individuals of African ancestries living in Western and East Sub-Saharan Africa and make comparisons with African and European ancestry populations living in Europe and the Americas in order to identify unique and common symptomatic clusters and biological mechanisms. This will help in developing a roadmap for the amelioration of growing health disparities by

establishing the methods, networks, expertise and knowledge base necessary for the rapid acceleration of depression genetics research.

Key objectives of the project will be to build capacity for psychiatric genomics within a network of African investigators, drawing on the substantial resources of the Psychiatric Genomics




Project PI, Country PIs and Co-PIs At DepGenAfrica Meeting at Witts University, Johannesburg, South Africa.



With our Cardiff Collaborator and C-PI for Nigeria (Niran Okewole)

Consortium (PGC). The project will train key individuals, building critical capacity within each network member, and engage local communities around the health research uses of genetic data. It will also develop processes for rapid and consistent sample collection, genotyping and data sharing and then leverage this information to compare the genetic architecture of depression and schizophrenia in low-income African ancestry populations, with African and European ancestries in high income settings thereby providing an infrastructure for accelerating advances in our understanding of psychiatric disorders.

For sample collections, three African centres were intentionally chosen at different stages in the collection of DNA samples, so that the project can strengthen capacity at each stage of the research process and enable learning across each centre. Three countries Malawi, Ethiopia and Nigeria will contribute to data collection and analysis; DNA extraction and genotyping will all be led from



South Africa. We have chosen to concentrate on depression as, these disorders account for a significant percentage of all clinical activity.

Ahmadu Bello University Zaria is the hub and coordinating centre for the research project in Nigeria and Professor Taiwo Lateef Sheikh is the Lead. The Zaria Centre will recruit 2000 cases with major depressive disorders from inpatient and outpatient health services across Nigeria and in addition 1000 healthy controls. Recruitment will be concentrated in Zaria/Kaduna, Sokoto, Maiduguri, Yola, Jos, Ilorin, Makurdi, Benin, Port Harcourt, Calabar, Benin, Enugu, Awka, Ibadan, Lagos representing the North West, North East, North Central, South South South, South East and

South West geopolitical regions of the country using our existing links to these sites and psychiatrists' networks.

Approaches and milestones: The project seeks to (1) develop existing networks and build clinical research capacity in Africa for psychiatric genomics, (2) develop standardised methods of data and sample collection, curation/storage and sharing and (3) develop standardised quality control (QC), imputation and analysis platforms. These will stimulate African-led ownership of research in psychiatric genomics and provide a basis for future research projects, investments and facilitate the development of local expertise and infrastructure that will stimulate African economies. Resources will be leveraged in the Psychiatric Genomics Consortium (PGC), the UK-based PGC group leads (CoIs:McIntosh, Walters and Breen), African Clinical Leadership (Sheikh, Teferra, Crampin) and Wellcome-supported genotyping arrays and related expertise (Msefula, Ramsay).



Country PIs at Witts university meeting



Visit to cradle of Mankind, South Africa



Africa Union/Africa CDC 2nd International Conference on Public Health in Africa, Kigali, Rwanda.


ACENTDFB-SUPPORTED POSTGRADUATE STUDENTS OF BIOCHEMISTRY DEPARTMENT INTERNATIONAL RESEARCH AWARDS

Two doctoral students, Ms Flore Edwidge Gouegni, Ms. Amaya Jobin Habila, and a Master student, Mr. Mukhtar Aliyu who are enrolled for the Biotechnology programs at the Department of Biochemistry, have made ABU proud by each winning internationally competitive research awards. The three awardees are supported by The African Centre of Excellence for Neglected Tropical Diseases and Forensic Biotechnology (ACENTDFB), which is a World bank-funded project aimed to contribute towards eliminating Africa-endemic tropical diseases through research and manpower development. ACENTDFB supports postgraduate studies in Biotechnology or Forensic Sciences offered in the Department of

Biochemistry, Ahmadu Bello University. All three awardees were mentored for the contest by Dr. Emmanuel Oluwadare Balogun, a staff of Biochemistry Department.

The Association of African Universities (AAU), with support from the World Bank, through the Africa Higher Education Centres of Excellence for Development Impact (ACE Impact) project launched its first Students Innovation Research Awards (SIRA) competition in September, 2022. The SIRA recognizes and promotes excellent research and innovation with both scientific and societal value that responds to Africa's developmental challenges. Four Hundred and

Twenty-Eight (428) applications covering five thematic disciplines (Agriculture, Applied Social Sciences/ Education, Environment, Health, and STEM) were received from ACE Impact students in the 11 participating countries (Benin, Burkina Faso, Cote d'Ivoire, Djibouti, Ghana, The Gambia, Guinea, Niger, Nigeria, Senegal and Togo). Following a transparent and rigorous review process, 15 research projects (three from each thematic discipline) were selected for the awards. The awards were presented at the closing ceremony of the 8th ACE Impact Regional Workshop held in Gambia from 14th -18th November 2022.



Ms. Flore Edwidge Gouegni making a presentation of her award-winning PhD research at 8th ACE Impact Regional Workshop held in Banjul, The Gambia from 14th -18th November 2022.



Mr. Mukhtar Aliyu receiving his certificate of research excellence on his MSc research work from the former Vice President of The Gambia, Late Mr. Badara Aliou Joof at the 8th ACE Impact Regional Workshop held in Banjul, The Gambia from 14th -18th November 2022.

Based on her PhD research titled "Immunogenic Potentials of Trypanosoma congolense Flagellar Pocket Membrane Bound Acid Phosphatase", Ms. Flore Gouegni won the first position under the Agriculture Thematic Area. Flore received a cash grant of \$4,000 and a certificate of research excellence. While

Mukhtar Aliyu, based on his research titled "Prevalence of Microsporidia in association with Plasmodium falciparum and Wuchereria bancrofti in Anopheles gambiae within Ahmadu Bello University, Zaria-Nigeria" won the 3rd position under Health Thematic Area. Mukhtar received \$2,000 and a certificate of

research excellence.

Ms. Amaya Jobin Habila submitted an abstract titled "Evaluation of the Immunoprotective Potential of Trypanosoma brucei Glycerol Kinase in Mice" from her PhD research for the Merck Foundation African Research Summit (MARS) 2022, which held on the

15th November, 2022 in Dubai. The focus of the summit was Vaccine Development and Cancer research. Amaya's work was selected and awarded 'Winner of The Best African Women Researchers Award MARS 2022'. The award comprises a certificate and three (3)

months Research Training Scholarship at an Indian research institution. The Award ceremony held via a video conference on the 1st February 2023 at 10 am - 1 pm Nigerian time. The MARS Awards aim to motivate and empower African young researchers and

women researchers to strengthen their research capacity and promote their contribution to STEM (Science, Technology, Engineering and Mathematics).



Ms. Amaya Jobin Habila, Winner of The Best African Women Researchers Award MARS 2022 and her certificate of award.

NIGERIAN LNG LIMITED PRIZE AWARD FOR SCIENCE 2022



Two Maize breeders from the Department of Plant Science, Institute for Agricultural Research, Professor Shehu Ado Garki and Dr. Muhyidin Oyekunle won the 2022 Nigeria Prize for Science Award of the Nigerian LNG Limited for their research on "Gains in Grain Yield of Released Maize (*Zea mays* L.) Cultivars under Drought and Well-Watered Conditions". The award was announced by the Prize Award Committee on Friday, 14th October 2022 at the Eko Hotels and Suites, Lagos. The Nigeria Prize for Science Award of the Nigerian LNG Limited is an annual award aimed at stimulating the advancement and application of Science and technology. It is awarded to scientists from anywhere in the world who help find solutions to a local or Nigerian problem as defined and advertised by the Advisory Board for the prize.

AFRICAN STUDIES (ASR) PRIZE FOR THE BEST AFRICA-BASED DOCTORAL DISSERTATION IN 2022: A CONTEXTUAL ANALYSIS OF SUFI SAINT PAINTINGS IN KANO, NIGERIA

By Nadir Abdulhadi Nasidi (PhD), Department of History



Sheriff Abdallah Marhaba, Gausu Nuhu Wali, Oil on Canvas, 92x61 cm, 1986, Dukawa, (Photograph: Nadir A. Nasidi, 2019)

Background: The Sufi saint painting being holy to its followers, Lewis maintains that it plays a number of roles, ranging from mediation to visual representation of the divine. Thus, religious artists use their unique skills for spiritual communication, with both the Saviour and His Saints whom they represent artistically. This is because, despite high level of Muslim iconoclasm, most Sufis believe in the visual representation of their saints. Meanwhile, this development created a lot of tension between mainstream Islam and its local adaptations as regards the legality or otherwise of visual imagery. Iconoclasm, as Jari posits, is not only restricted to Islam, it is also found in the doctrinal cleavages of other Abrahamic faith systems of Christianity and Judaism. In recent times, the ascendancy of puritanical Islamic sects

has foregrounding debates on the need for cultural iconoclasm which Sufi Islamic denomination of the Tijjaniyyah movement has resolutely rejected.

Since its inception, support for the Tijjaniyyah Sufi order in Kano by the emirs and Islamic scholars was part of the effort to break away from the political and more conservative religious hegemony of Sokoto Caliphate. This stance was also concretized with the invitation of Sheikh Ibrahim Niass in 1937 by the then Emir of Kano, Abdullahi Bayero to come to Kano, an invitation which Sokoto viewed with reservation. Niass's visits to Kano, especially in the 1950s as the Sāhib al-Faydhah (the owner of the divine flood) made him acceptable among the Tijjaniyyah scholars of Kano. From that time, Muslims began to visit Kaolak,

Senegal, Niass's hometown to seek for his barakah (blessing) and spiritual guidance. It was during such visits that the people of Kano discovered the paintings of Sheikh Amadu Bamba, the founder of the Muridiyyah Sufi order, which they copied and adapted, but this time around, to visually glorify the Sufi saints of Tijjaniyyah and much later, the Qādiriyyah brotherhood. Most of these paintings are murals largely found within Kano metropolis. While some Muslims, especially of the Wahabi/Salafi ideological bent negate human figurative arts including that of the Sufis using textual interpretations of the Islamic canons (Qur'an and Sunnah), the Sufis affirm its legality using purely esoteric explanations of the same canons. In view of this therefore, the diverse perspectives on the nature, origin, legality and compositions of sacred Sufi paintings have inspired the researcher into a contextual analysis of Sufi saint painting in Kano, Nigeria focusing mainly on its history, artists, media and styles, as well as its functions to the socio-political and economic life of the people of Kano.

Significant findings from the Research: The research attempted a contextual analysis of Sufi saint paintings in Kano, Nigeria through its historical evolution. The problem of the study was the literary gap on the nature, origin and functions of Sufi saint paintings in Kano. It therefore, provides a contextual interpretation of Sufi saint paintings in Kano. Meanwhile, the analysis, discussions, observations, findings, conclusion and recommendations of the research were based on the objectives of the study, which were to; (1) trace the history and nature of Sufi saint paintings in Kano, (2) identify the Sufi saint painters of Kano, (3) examine the media and styles used by the Sufi artists, (4) interrogate the position of painting amongst the Islamic scholars of the Tijjaniyyah and Qādiriyyah brotherhoods; and (5) contextually interrogate the values of Sufi

saint paintings in Kano.

The study expanded the boundaries of research as it relates to the history, nature, forms, styles, and contents of art generally in Kano, but specifically the Sufi saint paintings, their relevance contextually to the socio-political and economic life of the people of Kano. In this regard therefore, the research helps to complement the dearth of literature, as much as the saint paintings in Kano are concerned apart from contributing to the ongoing debates and contestations about the legality or rejection of artistic visual representations of reality. Due to the nature of the research, two theoretical frameworks were adopted; Firth Theory of Contextualization and Gestalt theory of visual imagery, so as to properly analyse as well as contextualize the Sufi saint paintings within Kano's social, economic and political domains. As the former is used to interpret the contexts, the latter helps to appreciate the images and their aesthetics.

In the research, a number of relevant literature were reviewed, particularly on issues related to the historical development of Islamic art, the meaning of Sufism, iconoclasm and Sufi saint paintings, Islamic artists and their artistic productions, as well as sacred arts in Kano. The reviewed literature provides insights on whether to affirm, or debunk certain views and propositions in regards to human figuration in Islam. Meanwhile, a qualitative research methodology was adopted in the study, augmented by a descriptive, historical and contextual data analysis. Furthermore, the discussions and analysis of the selected works of Sufi saint painters in Kano was basically broken down into four important, but related sub-headings namely; The Introduction of Sufi saint paintings in Kano, Brief Biographies of Some Sufi Saint Painters in Kano, The Contextual Analysis of Sufi saint Paintings in Kano, as well as, the

Position of Painting amongst the Islamic Scholars of the Tijjaniyyah and Qādiriyyah Sufi orders. Thus, the research identified, purposively sampled and discussed a total number of 10 Sufi saint painters in Kano. Besides, forty three (43) artworks produced by the artists were identified and thirty (30) are documented, analyzed and appreciated.

Based on the findings and discussions, the study has identified some prominent Sufi painters in Kano and provides their individual biographies. It revealed that though there are contestations among many Sufi scholars regarding representational art, they unanimously believe in the semiotic meanings attributed to colours, especially the ones appearing frequently in Sufi visual discourses. The study equally discovered the contextual values of Sufi paintings in Kano, especially to the socio-economic and political life of the people. It also observed that Sufi saint paintings in Kano are generally categorized into four, while it established that Sheikh Ibrahim Niass is the most predominant Sufi saint featured in most Sufi paintings in Kano.



Dr. Nadir A. Nasidi
Department of Fine Art
Ahmadu Bello University, Zaria

References:

- Lewis, G. K., (2010). Sacred Arts Study: Thomas Merton's Guides for Arts and Worship. Thomas Merton Centre, pp. 155-157.
- Jat J. J. (2007). Image and Form of Indigenous Christian Art in Catholic Churches in Plateau State (Unpublished PhD Thesis). Ahmadu Bello University, Zaria, Department of Fine Art.

Links to works accruing from the study

- Nasidi, N.A. (2020). 'A Contextual Analysis of Sacred Qādiriyyah Sufi Paintings in Kano, Nigeria'. Vestiges: Traces of Record, Vol. 6, Institute of Social and Cultural Anthropology, University of Oxford, pp. 48-63. ISSN- 2058-1963, <http://www.vestiges-journal.info/>.
- Nasidi, N.A. (2022). 'Some Biographical Notes on Artists of Sacred Sufi Paintings in Kano, Nigeria', Journal of West African History, Michigan State University, Vol. 7, no. 2 (Forthcoming). <https://scholarlypublishingcollective.org/msup/jwah>.
- Nasidi, N.A. 'From Art to Blasphemy: Northern Nigerian Muslim Responses to Muazu Mohammed Sani's Religious Paintings', A paper presented at an E-Conference on "Performing Theology", which took place on 20 - 22 May, 2022, Technische Universität, Dresden, Germany. https://tudresden.de/gsw/phil/ikt/systematik/die-professur/forschungsnetzwerke/theology-performancepolitics-in-a-nutshell?set_language=en.
- Nasidi, N. A. (2022). From the Secular to the Sacred: Sufi Representational Art in Kano', A paper presented at a Conference/Workshop on 'Multiple Secularities in Africa and the Diaspora', Leipzig University, Germany, June 1-3 https://www.multiple-secularities.de/media/workshop_multiple_secularities_in_africa_and_the_diaspora_programme_1.pdf.
- Nasidi, N. A (2019). Sheikh Ibrahim Niass and the Making of Sacred Sufi Paintings in Kano (1946-1975) Zaria Archaeology Papers, 12, 177-195. Department of Archaeology and Heritage Studies, Ahmadu Bello University, Zaria, https://www.researchgate.net/profile/Nadir-Nasidi/publication/344877290_Sheikh_Ibrahim_Niass_and_the_Making_of_Sacred_Sufi_Paintings_in_Kano_1946-1975/links/5f9624ea299bf1b53e45d7e7/Sheikh-Ibrahim-Niass-and-the-Making-of-Sacred-Sufi-Paintings-in-Kano-1946-1975.pdf.

6. Nasidi, N. A. & Muhammad, A. (2019). Iconoclasm and the Historical Evolution of Sufi Painting. *Egghead*, 4(2), 71-81. Department of Fine Art, Ahmadu Bello University, Zaria. <https://scholar.google.com/scholar?cluster=4955960604930818592&hl=en&oi=scholar>.

7. Nasidi, N. A. (2019). A Biographical Study of Three Sufi Painters in Kano, *Environ: Journal of Environmental Studies*, 4(8), 56-67. Faculty of Environmental Design, Ahmadu Bello University, Zaria.

https://www.researchgate.net/publication/347952509_A_Biographical_Study_of_Three_Sufi_Painters_in_Kano.

Samples of the Sacred Sufi Paintings The following are examples of Sufi saint paintings of Kano, Nigeria:



Plate 2: Sheikh Ibrahim Niass, Abubakar Daheer (A.D. Master), Paint on Wall, 150x130 cm, 2016. (Photograph: Nadir A. Nasidi, 2019)



Plate 3: Sheikh Nasir Kabara, Ado Abdu, Paint on Wall 157x183 cm, 2000, Dala, (Photograph: Nadir A. Nasidi, 2018)

Publications from Research Groups and Units

SOIL MECHANICS AND GEO-ENVIRONMENTAL ENGINEERING RESEARCH GROUP, DEPARTMENT OF CIVIL ENGINEERING

Members: Prof. K. J. Osinubi (Team Lead), Prof. A. O. Eberemu, Prof. T. S. Ijimdiya, Dr. J. Ochepe, E. A. Nyebe, I. Iliyasu, D.M. Bara'u, I. Suleiman, I. Y. Surakat, J. P Adebisi, L. Idris and D. Aminu

Publications:

- Osinubi, K. J., Eberemu, A. O., Yohanna, P. & Azige, P. (2022). Effect of selected admixtures on the geotechnical properties of black cotton soil. *Algerian Journal of Engineering and Technology*, 6, 105-112.
- Osinubi, K. J., Eberemu, A. O., Yohanna, P. & Azige, P. (2022). Reliability based predictive model for estimating shear strength values of locust bean waste ash compacted black cotton soil. *Cleaner Materials*, 5 (2022) 100114. <https://doi.org/10.1016/j.clema.2022.100114>
- Sani, J. E., Moses, G., Etim, R. K., Wilson, U.N. & Babatunde, A. O. (2022). Stabilization of lateritic soil with cement and treated sisal fibre. *ACTA TECHNICA CORVINIENSIS – Bulletin of Engineering*, 1, 41-47.
- Makwin, H. L., Ojo, E. B., Yisa, G. L. & Ekeyi, I. O. (2022). Agro waste-based binders for the stabilization of tropical soils. *International Journal of Advances in Engineering and Management*, 4(8), 936-945.
- Yohanna, P., Etim, R. K., Ijimdiya, T. S., Osinubi, K. J. & Buki, J. M. (2022). Reliability analysis of compaction characteristics of tropical black clay admixed with lime and iron ore-silica based dominant tailing. *Epitoanyag – Journal of Silicate Based and Composite Materials*, 74(1), 13-20. <https://doi.org/10.14382/epitoanyag-jsbcm.2022.3>
- Onyelowe, K. C., Tome, S., Ebid, A. M, Usungedo, T., Van, B. D., Etim, R. K., Onuoha, I. C. & Attah, I. C. (2022). Effect of desiccation on ashcrete (HSDA)-treated soft soil used as flexible pavement foundation: zero carbon stabilizer approach. *International Journal of Low-Carbon Technologies*, 17, 563-570. <https://doi.org/10.1093/ijlct/ctac042>

7. Attah, I. C., Etim, R. K., Alaneme, G. U., Ekpo, D. U. & Usanga, I. N. (2022). Scheffe's approach for single additive optimization in selected soils amelioration studies for cleaner environment and sustainable subgrade materials. *Cleaner Materials*. <https://doi.org/10.1016/j.clema.2022.100126>
8. Ezeokpube, G. C., Ahaneku, I. E., Alaneme, G. U., Attah, I. C., Etim, R. K., Olaiya, B. C. & Udousoro, I. M. (2022). Assessment of mechanical properties of soil-lime-crude oil contaminated soil blend using regression model for sustainable pavement foundation construction. *Advances in Materials Science and Engineering*, 2022, <https://doi.org/10.1155/2022/7207842>
9. Gadzama, E. W., Eberemu, A. O., Ijimdiya, T. S. & Osinubi, K. J. (2022). Strength characteristics of compacted lateritic soil using microbially induced calcite precipitate under sterilized and unsterilized condition. *Arid Zone Journal of Engineering, Technology and Environment*. 8 (3), 1 - 18. <https://azojete.com.ng/index.php/azojete/issue/view/39>
10. Gadzama, E. W., Eberemu, A. O., Ijimdiya, E. W. and Osinubi, K. J. (2022). Effect of *Sporosarcina pasteurii*-induced calcite precipitate on the hydraulic conductivity of compacted bio-cemented lateritic soil." *Jostum Journal of Engineering*, 1(1), 145-159.
11. Gadzama, E. W., Ijimdiya, T. S., Eberemu, A. O. & Osinubi. (2022). Influence of injection pressure on the hydraulic conductivity of compacted bio-cemented lateritic soil. *Nigeria Journal of Engineering Science and Technology Research*, 8(1), 29-41.
12. Yohanna, P., Eberemu, A. O., Ijimdiya, T. S. & Osinubi, K. J. (2022). The effect of *Bacillus coagulans* and moulding water content on the unconfined compressive strength of lateritic soil. *Engineering Science and Technology*, 3(1), 69-83. DOI: <https://doi.org/10.37256/est.3120221286/>.
13. Yohanna, P., Ijimdiya, T. S., Osinubi, K. J. & Eberemu, A. O. (2022). A laboratory study on water transfer properties of unsaturated compacted lateritic soil – *Bacillus coagulans* mixtures. *Algerian Journal of Engineering and Technology*, 6, 19-28.
14. Yohanna, P., Ijimdiya, T. S., Eberemu, A. O. & Osinubi, K. J. (2022). Influence of compactive effort on the hydraulic performance of tropical red soil-*Bacillus coagulans* mixtures. *Journal of Civil Engineering*, 15(1), 62-87.
15. Onyelowe, K. C., Mojtahedi, F. F., Ebid, A. M., Rezaei, A., Osinubi, K. J., Eberemu, A. O., Salahudeen, B., Gadzama, E. W., Rezazadeh, D., Jahangir, H., Yohanna, P., Onyia, M. F., Jalal, F. E., Iqbal, M., Ikpa, C., Obianyo, I. I. & Rehman Z. U. (2023) Selected AI optimization techniques and applications in geotechnical engineering, *Cogent Engineering*, 10(1), <https://doi.org/10.1080/23311916.2022.2153419>
16. Etim, R. K., Ijimdiya, T. S., Eberemu, A. O. & Osinubi, K. J. (2022). Compatibility interaction of landfill leachate with lateritic soil bio-treated with *Bacillus megaterium* using MICP technique: criterion for barrier material in waste containment. *Cleaner Materials*. <https://doi.org/10.1016/j.clema.2022.100110>
17. Eberemu, A. O. (2022). Sustainability in Geotechnical/Geoenvironmental Engineering. Keynote paper presented at the National Conference of the Nigerian Institution of Geotechnical Engineers. 31st October – 2nd November (pp. 2 – 18), Port Harcourt.
18. Eberemu, A. O., Yohanna, P., Aliyu, M & Abdu-Aguye, A. (2022). Consolidation characteristics of rice husk ash treated lateritic soil. *Malaysian Journal of Civil Engineering*, 34(1), 19–28.
19. Yohanna, P., Kanyi, I. M., Aondover, C. M. & Mije, F. G. (2022). Effect of rice husk ash-based geo-polymer on some geotechnical properties of lateritic soil. *Journal of Civil Engineering*, 14(1), 41-54.
20. Geotechnical Investigation and Soil Report for Maintenance of Selected Road Sections using Base Seal Stabilization at Arungungu - Birnin Kebbi road, Kebbi, Gwagwalada, Abuja and Benin, Edo State. Prepared for Federal Road Maintenance Agency (FERMA).
21. Eberemu, A. O., Obada, D. O., Bako, R. B., Ahmed, A. S., Anafi, F. O., Osinubi, K. J. (2022). Enhancing the Interest of Undergraduate Students in Geotechnical Engineering Using the CACPLA Pedagogy. *ASCE GeoCongress GSP 336*, pp 534 -543.
22. Tukur, A. L., Gadzama, E. W., Ikechukwu, H. B. & Abubakar, A. U. (2022). Application of Pavement Management Systems (PMS) Strategies in Planning and Maintenance of Internal Road Networks in MAU Yola. *Proceedings of Nigerian Institution of Civil Engineers Book of abstract 20th International Conference and Annual General Meeting Eko-Akete 2022*.

MATERIALS PHYSICS RESEARCH GROUP DEPARTMENT OF PHYSICS

Members: Dr. Lawal Mohammed (Group Lead), Prof. A. A. Abdelmalik, Dr. Abdulsalam Ismaila Galadima, Dr. Abubakar Khaleed Abubakar, Dr. Yusuf Abubakar Musa, Dr. Abdulraheem Aliyu, Yahaya Aliyu, Dr. Bashir Yusuf, Sa'idu Maidawa, Nura Ibrahim

1. Abdelmalik, A. A. (2022). A Day in the Life of a High-Voltage Materials Physics Laboratory, *IEEE Electrical Insulation Magazine*, 38(6), 16-23, November/December, [10.1109/MEI.2022.9916181](https://doi.org/10.1109/MEI.2022.9916181).
2. Oparanti, S. O., Salaudeen, I. K., Adekunle, A. A., Galadima, A. I. & Abdelmalik, A. A. (2022). Physicochemical and Dielectric Study on Nigerian *Thevetia Peruviana* as a Potential Green Alternative Fluid for Transformer Cooling/Insulation, *Waste and Biomass Valorization*, 10.21203/rs.3.rs-1686156/v1
3. Oparanti, S. O., Adekunle, A. A., Oteikwu, V. E., Galadima, A. I. & Abdelmalik, A. A. (2022). An experimental investigation on composite methyl ester as a solution to environmental threat caused by mineral oil in transformer insulation, *Biomass Conversion and Biorefinery*, 10.1007/s13399-022-03286-3, 2190-6823.
4. Abdelmalik, A. A., Ogbodo, M. O., Abubakar, Y. M., Galadima, A. I., Aliyu, A. & Jonah, S. A. (2022). Influence of neutron irradiation on the mechanical and dielectric properties of epoxy/titanium oxide nanocomposite, *Radiation Physics and Chemistry*, 198, 110230, <https://doi.org/10.1016/j.radphyschem.2022.110230>.
5. Tambuwal, F. R., Oparanti, S.O., Abdulkadir, I. Sadiq, U. & Abdelmalik, A.A. (2022). Investigative study on the AC and DC breakdown voltage of nanofluid from *Jatropha-Neem* oil mixture for use in oil-filled power equipment. *Int J Adv Manuf Technol*, <https://doi.org/10.1007/s00170-021-08447-8>.
6. Oparanti, S. O., Abdelmalik, A. A., Khaleed, A. A., Abifarin, J. K., Suleiman, M. U. & Oteikwu, V. E. (2022). Synthesis and characterization of cooling biodegradable nanofluids from non-edible oil for high voltage application, *Materials Chemistry and Physics*, 277, 125485, <https://doi.org/10.1016/j.matchemphys.2021.125485>.
7. Oparanti, S. O. & Abdelmalik, A.A. (2022). Dielectric Nanoparticles Blended with Natural Ester a Promising Solution to Sustainable Development Threat, *Annual Report IEEE Conference on Electrical Insulation and Dielectric Phenomena*, <https://doi.org/10.1109/CEIDP55452.2022.9985340>.

8. Kaneez F., Quratul A., Lawal M., Muhammad J., Abdul M. K., Masood Y. & Junaid M. (2022). Ground state electronic structure, optical and thermoelectric response of Zintl phase $MgAl_2X_2$ ($X = C, Sb$) for renewable energy applications: *Physica B: Condensed Matter* 631, 413688. <https://doi.org/10.1016/j.physb.2022.413688>.
9. Nura I., Lawal M. & Ridwan A. (2022). Graphene-like silicon carbide layer for potential safe anode lithium-ion battery: A first principle study. *Science Talks* 4 100075 10.1016/j.sctalk.2022.100075.
10. Ibrahim, N., Garba, N. N., Mohammed, U. M., Kankara, L., Aliyu, M. & Aliyu, Y. (2022). Electronic properties and structural phase transition of IV-IV and III-V semiconductor pressure: A first principles approach. *BAJOPAS, Special Conference Edition* 13(1), <http://dx.doi.org/10.4314/bajopas.v13i1.57S>.
11. Ibrahim, N., Ahmed, R. A., Huda A. & Ichwani, R. (2022). Electronic structures and thermoelectric properties of heavily doped n-type ZrCoBi from first principles calculations. *Materials Today Communications* 32. <https://doi.org/10.1016/j.mtcomm.2022.103908>.
12. Junaid M., Ahmed S. J., Quratul A., Lawal M. & Masood, Y. (2022). Magneto-electronic, and optical properties of reduced layered hybrid $Zn(C_4H_4N_2)V_4O_{10}$ complex: A DFT study. *Journal of Optoelectronics and Advanced Materials*, 24(11-12), 576 – 583.
13. Omotoso, E., Khaleed, A. A. & Igumbor, E. (2022). Effect of room temperature annealing on Ni/4H-Silicon Carbide Schottky contacts after alpha particle irradiation at high fluence. *Samuel Adegboyega University (SAU) Science-Tech Journal* 7(1) 78-89.
14. Murtala, M. L., Zangina, T., Maharaz M. N., Abdussalam, B. S., Abdulsalam, I. G., Kafilu, B. D. & Makiyyu, A. M. (2022). Dielectric Properties of Fresh Roma and Cherry Tomato Samples at Different Frequencies and Temperatures. *Abubakar Tafawa Balewa University Journal of Science, Technology and Education*, 9(4), 290-297. www.atbuftejoste.com.
15. Abdulsalam, I. G., Abdelmalik, A. A., Maharaz, M. N., Auwal, S. M. & Oparanti, S. O. (2022). Physico-Chemical Characterization of a Multiparticle Vegetable Oil-Based Nanofluid for High Voltage Application. *Abubakar Tafawa Balewa University Journal of Science, Technology and Education*, 9(4), pp. 298-303. www.atbuftejoste.com.
16. Abdulsalam, I. G. and Zainab, Y. Y. (2022). Variational Effect of Elevation on the Range of Energetic Boron Ions in an Amorphous Silicon Target. *Bayero Journal of Pure and Applied Sciences*, 13(1), 343-346. <http://dx.doi.org/10.4314/bajopas.v13i1.6S>.
17. Asiru, T. M., Tella, A., Akingbehin, K. A., Mba, O. & Abubakar, K. (2022). *Nelson Functional Mathematics for Senior Secondary Schools 2 & 3, Revised Edition*.
18. Galadima, A. I. & Yusuf, Z. Y. (2022). Variational Effect of Elevation on the Range of Energetic Boron Ions in an Amorphous Silicon Target. Paper presented at the Bayero University, Kano International Science Conference (BUKISC 2022), Mahmud Tukur Theatre, Old Campus, BUK, Nigeria, 8-10 February.
19. Galadima, A. I., Abdelmalik, A. A., Edika, E.C. & Oparanti, S. O. (2022). DC Breakdown Voltage Analysis of a Multiparticle (SiO_2-TiO_2) Vegetable Oil-Based Nanofluid. Presented at the Materials Science and Technology Society of Nigeria (MSN), 21st Annual International Conference held at the Raw Materials Research and Development Council, Maitama, Abuja, Nigeria. 15-18 November.
20. Abdelmalik, A. A., Hamzat, A., Oparanti, S. O., Galadima, A. I., Abdurraheem, A., Khaleed, A. A. & Abubakar, Y. M. (2022). High Voltage Insulating Materials, Electric power, and sustainable energy supply. Paper presented at the Materials Science and Technology Society of Nigeria (MSN), 21st Annual International Conference held at the Raw Materials Research and Development Council, Maitama, Abuja, Nigeria. 15-18 November.
21. Abdelmalik, A. A., Galadima, A. I., Abdurraheem, A., Abubakar, Y. M. & Khaleed, A. A. The Ahmadu Bello University's High Voltage Materials Laboratory (The Cubicle) (2022). Paper presented at the Air Force Institute of Technology (AFIT) 1st National Faculty of Science Conference held at Ibrahim Alfa Hall, AFIT, Air Force Base, Mando, Kaduna, 21-23 November.
22. Oparanti, S. O., Adewunmi, A. A., Galadima, A. I. & Abdelmalik, A. A. (2022). Compatibility of Transformer Insulating Paper (Kraft paper) with Nanofluid prepared from Neem Oil Ester. *African Light Source (AfLS4-2022) and African Physical Society (AfPS-2022) Joint Virtual Conference*, 14th November.
23. Ibrahim, N. & Mohammed, L. (2022). Graphene-Like Silicon Carbide Layer for Safe Anode Lithium Ion Battery: A First Principle Study. *The Advances in Surfaces, Interfaces and Interphases Conference*, 15-18 May.
24. Oparanti, S. O. & Abdelmalik, A. A. (2022). Dielectric Nanoparticles Blended with Natural Ester a Promising Solution to Sustainable Development Threat. Paper presented virtually at the IEEE Conference on Electrical Insulation and Dielectric Phenomena, held at Denver, Colorado, USA from 30 October – 2 November.

PHYSICAL CHEMISTRY RESEARCH GROUP, DEPARTMENT OF CHEMISTRY

Members: Prof. Adamu Uzairu (Group Lead), Prof. Gideon Adamu Shallangwa, Dr. Sani Uba, Dr. Stephen Eyije Abechi, Dr. Abdullahi Bello Umar and Dr. Muhammad Tukur Ibrahim

Publications:

1. Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. (2022). Computational modeling and analysis of the theoretical structure of thiazolino 2-pyridone amide inhibitors for *Yersinia pseudo-tuberculosis* and *Chlamydia trachomatis* Infectivity. *Bull Sci Res*, 4(1), 14-39. Web link: [Bulletin of Scientific Research 4\(1\):14-39 https://doi.org/10.54392/bsr2212](https://doi.org/10.54392/bsr2212)
2. Adawara, S., Adamu, G., Mamza, P. & Abdulkadir, I. (2022). Chemoinformatic Design of Phthalazinone Analogues as Novel Dengue Virus NS2B-NS3 Protease Inhibitors with Enhanced Pharmacokinetics. *Advanced Journal of Chemistry-Section A*, 5(2), 175-189. http://www.ajchem-a.com/article_147374.html DOI: 10.22034/AJCA.2022.322426.1297
3. Adawara, S., Adamu, G., Mamza, P. & Abdulkadir, I. (2022). In-silico studies of some Oxadiazole Hybrids as Potential inhibitors of Dengue Virus NS2B-NS3 Protease. *Advanced Journal of Chemistry-Section A*, 5(2), 118-137. http://www.ajchem-a.com/article_146463.html <https://doi.org/10.22034/ajca.2022.320210.1291>
4. Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. (2022). A 2D-QSAR, Homology Modeling, Docking, ADMET, and Molecular Dynamics Simulations Studies for Assessment of a Novel SARS-Cov-2 and *Pseudomonas Aeruginosa* Inhibitors. *J Virol Viral Dis*, 2(2). <https://www.acquirepublications.org/Journal/Virology/PDF/JVVD2200106.pdf>

5. Ajala, A., Uzairu, A., Shallangwa, G. & Abechi, S. (2022). In-silico design, molecular docking and pharmacokinetics studies of some tacrine derivatives as anti-Alzheimer agents: theoretical investigation. *Adv J Chem Sect A*, 5(1), 59-69. http://www.ajchem-a.com/article_144077.html
<https://doi.org/10.22034/ajca.2022.321171.1292>
6. Ibrahim, M. T. & Uzairu, A. (2022). Structure-Based Identification of Some Potential Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) With In-silico Assessment of Their Pharmacokinetic Features and Quantum Chemical Calculations. *Advanced Journal of Chemistry-Section A*, 5(4), 333-344. <https://doi.org/10.22034/AJCA.2022.360821.1332>
7. Ejeh, S., Uzairu, A., Shallangwa, G., Abechi, S. & Ibrahim, M. (2022). In Silico Identification of Some Novel Ketoamides as Potential Pan-Genotypic HCV NS3/4A Protease Inhibitors with Drug-Likeness, Pharmacokinetic ADME Profiles, and Synthetic Accessibility Predictions. *Advanced Journal of Chemistry-Section A*, 5, 197. http://www.ajchem-a.com/article_148357.html <https://doi.org/10.22034/ajca.2022.329332.1302>
8. Ameji, J., Uzairu, A., Shallangwa, A. & Uba, S. (2022). Molecular docking study and insilico design of novel drug candidates against salmonella typhi. *Advanced Journal of Chemistry-Section B*, 4, 281-298. <https://doi.org/10.22034/ajcb.2022.366678.1129>
9. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S. & Umar, A. B. (2022). In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. *Bulletin of the National Research Centre*, 46(1), 2. <https://bnrc.springeropen.com/articles/10.1186/s42269-021-00690-z>
10. Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. (2022). Structure-based simulated scanning of Rheumatoid Arthritis inhibitors: 2D-QSAR, 3D-QSAR, Docking, Molecular dynamics simulation, and Lipophilicity indices calculation. *Scientific African*, 15, e01088. <https://doi.org/10.1016/j.sciaf.2021.e01088>
11. Ugbe, F. A., Shallangwa, G. A., Uzairu, A. & Abdulkadir, I. (2022). Theoretical activity prediction, structure-based design, molecular docking and pharmacokinetic studies of some maleimides against Leishmania donovani for the treatment of leishmaniasis. *Bulletin of the National Research Centre*, 46(1), 92. <https://bnrc.springeropen.com/articles/10.1186/s42269-022-00779-z>
12. Ugbe, F. A., Shallangwa, G. A., Uzairu, A. & Abdulkadir, I. (2022). Theoretical modeling and design of some pyrazolopyrimidine derivatives as Wolbachia inhibitors, targeting lymphatic filariasis and onchocerciasis. *In Silico Pharmacology*, 10(1), 8. <https://doi.org/10.1007/s40203-022-00123-3>
13. Ajala, A., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2022). 2D QSAR, design, docking study and ADMET of some N-aryl derivatives concerning inhibitory activity against Alzheimer disease. *Future Journal of Pharmaceutical Sciences*, 8(1), 30. <https://fjps.springeropen.com/articles/10.1186/s43094-022-00420-w>
14. Aminu, K. S., Uzairu, A., Umar, A. B. & Ibrahim, M. T. (2022). Salicylic acid derivatives as potential α -glucosidase inhibitors: Drug design, molecular docking and pharmacokinetic studies. *Bulletin of the National Research Centre*, 46(1), 162. <https://bnrc.springeropen.com/articles/10.1186/s42269-022-00853-6>
15. Akinola, L. K., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2022). Quantitative structure-activity relationship modeling of hydroxylated polychlorinated biphenyls as constitutive androstane receptor agonists. *Structural Chemistry*, 1-14. <https://link.springer.com/article/10.1007/s11224-022-01992-2>
16. Ugbe, F. A., Shallangwa, G. A., Uzairu, A. & Abdulkadir, I. (2022). Molecular Docking Screening and Pharmacokinetic Studies of Some Boron-Pleuromutilin Analogues against Possible Targets of Wolbachia pipientis. *Journal of Molecular Docking*, 2(1), 29-43. <https://journal.umpr.ac.id/index.php/jmd/article/view/3450>
17. Abdullahi, M., Uzairu, A., Shallangwa, G. A., Mamza, P. A. & Ibrahim, M. T. (2022). In-silico modelling studies of 5-benzyl-4-thiazolinone derivatives as influenza neuraminidase inhibitors via 2D-QSAR, 3D-QSAR, molecular docking, and ADMET predictions. *Heliyon*, 8(8), <https://doi.org/10.1016/j.heliyon.2022.e10101>
18. Ibrahim, Z. Y. U., Uzairu, A., Shallangwa, G. A., Abechi, S. E. & Isyaku, S. (2022). Virtual screening and molecular dynamic simulations of the antimalarial derivatives of 2-anilino 4-amino substituted quinazolines docked against a Pf-DHODH protein target. *Egyptian Journal of Medical Human Genetics*, 23(1), 119. <https://jmhg.springeropen.com/articles/10.1186/s43042-022-00329-2>
19. Abdullahi, M., Uzairu, A., Shallangwa, G. A., Mamza, P. A. & Ibrahim, M. T. (2022). Computational modelling studies of some 1, 3-thiazine derivatives as anti-influenza inhibitors targeting H1N1 neuraminidase via 2D-QSAR, 3D-QSAR, molecular docking, and ADMET predictions. *Beni-Suef University Journal of Basic and Applied Sciences*, 11(1), 104. <https://bjbas.springeropen.com/articles/10.1186/s43088-022-00280-6>
20. Ajala, A., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2022). Structure-based drug design of novel piperazine containing hydrazone derivatives as potent Alzheimer inhibitors: molecular docking and drug kinetics evaluation. *Brain Disorders*, 7, 100041. <https://doi.org/10.1016/j.dscb.2022.100041>
21. Oyegoke, T., Dabai, F. N., Waziri, S. M., Uzairu, A. & Jibril, B. E. Y. (2022). Impact of Mo and W on CrXO₃ (X= Cr, Mo, W) Catalytic Performance in a Propane Non-oxidative Dehydrogenation Process. *Kemija u industriji: Časopis kemičara i kemijskih inženjera Hrvatske*, 71(9-10), 583-590. <https://doi.org/10.15255/KUI.2022.006>
22. Oyegoke, T., Dabai, F. N., Waziri, S. M., Uzairu, A. & Jibril, B. E. Y. (2022). Utjecaj Mo i W na katalitička svojstva CrXO₃ (X= Cr, Mo, W) u procesu neoksidativne dehidrogenacije propana. *Kemija u industriji: Časopis kemičara i kemijskih inženjera Hrvatske*, 71(9-10), 583-590. <https://hrcak.srce.hr/clanak/410568> <https://doi.org/10.15255/KUI.2022.006>
23. Aminu, K. S., Uzairu, A., Abechi, S. E., Shallangwa, G. A. & Umar, A. B. (2022). Ligand-based drug design, molecular docking and pharmacokinetic studies of some series of 1, 4-dihydropyridines derivatives as human intestinal maltase-glucoamylase inhibitor. *Chemical Data Collections*, 41, 100911. <https://doi.org/10.1016/j.cdc.2022.100911>
24. Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. (2022). Theoretical Investigation of the Cooperation of Iminoguanidine with the Enzymes-Binding Domain of Covid-19 and Bacterial Lysozyme Inhibitors and their Pharmacokinetic Properties: Iminoguanidine Derivatives as Multi-target Lead Compound Against Covid-19 and Pseudomonas aeruginosa. *Journal of the Mexican Chemical Society*, 66(4). <https://doi.org/10.29356/jmcs.v66i4.1726>
25. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S. & Umar, A. B. (2022). Structure Based Design of Some Novel 3-Methylquinoxaline Derivatives Through Molecular Docking and Pharmacokinetics Studies as Novel VEGFR-2 Inhibitors. *Chemistry Africa*, 1-12. <https://link.springer.com/article/10.1007/s42250-022-00485-3>
26. Ejeh, S., Uzairu, A., Shallangwa, G. A., Abechi, S. E. & Ibrahim, M. T. (2022). Structure-based design, drug-likeness, and pharmacokinetic studies of novel substituted pyrimidine derivatives as potent HCV NS3/A4 protease inhibitors. *Biocatalysis and Agricultural Biotechnology*, 46, 102539. <https://doi.org/10.1016/j.bcab.2022.102539>

27. Ugbe, F. A., Shallangwa, G. A., Uzairu, A. & Abdulkadir, I. (2022). Molecular docking-based virtual screening, molecular dynamic simulation, and 3-D QSAR modeling of some pyrazolopyrimidine analogs as potent anti-filarial agents. *In Silico Pharmacology*, 10(1), 21. <https://link.springer.com/article/10.1007/s40203-022-00136-y>
28. Ajala, A., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2022). Computational and pharmacokinetics studies of 1, 3-dimethylbenzimidazolinone analogues of new proposed agent against Alzheimer's disease. *Beni-Suef University Journal of Basic and Applied Sciences*, 11(1), 1-19. <https://bjbas.springeropen.com/articles/10.1186/s43088-022-00231-1>
29. Ejeh, S., Uzairu, A., Shallangwa, G. A., Abechi, S. E. & Ibrahim, M. T. (2022). In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach. *Bulletin of the National Research Centre*, 46(1), 1-11. <https://bnrc.springeropen.com/articles/10.1186/s42269-022-00796-y>
30. Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. (2022). QSAR, homology modeling, and docking simulation on SARS-CoV-2 and pseudomonas aeruginosa inhibitors, ADMET, and molecular dynamic simulations to find a possible oral lead candidate. *Journal of Genetic Engineering and Biotechnology*, 20(1), 1-17. <https://jgeb.springeropen.com/articles/10.1186/s43141-022-00362-z>
31. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S. & Umar, A. B. (2022). Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents. *Bulletin of the National Research Centre*, 46(1), 1-25. <https://bnrc.springeropen.com/articles/10.1186/s42269-022-00869-y>
32. Ugbe, F. A., Shallangwa, G. A., Uzairu, A. & Abdulkadir, I. (2022). A combined 2-D and 3-D QSAR modeling, molecular docking study, design, and pharmacokinetic profiling of some arylimidamide-azole hybrids as superior L. donovani inhibitors. *Bulletin of the National Research Centre*, 46(1), 1-24. <https://bnrc.springeropen.com/articles/10.1186/s42269-022-00874-1>
33. Ibrahim, Z. Y. U., Uzairu, A., Shallangwa, G. A., Abechi, S. E. & Isyaku, S. (2022). Quantitative Structure-Activity Relationship, Structure-based Design, and ADMET studies of pyrimethamine and cycloguanil analogs inhibitors of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS). *Chemical Physics Impact*, 5, 100132. <https://www.sciencedirect.com/science/article/pii/S2667022422000706>
34. Ajala, A., Uzairu, A., Shallangwa, G. A. & Stephen, A. E. (2022). QSAR, Molecular Docking, Dynamic Simulation and Kinetic Study of Monoamine Oxidase B Inhibitors as Anti-Alzheimer Agent. *Chemistry Africa*, 1-14. <https://link.springer.com/article/10.1007/s42250-022-00561-8>
35. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S. & Umar, A. B. (2022). Molecular Docking, ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors. *Egyptian Journal of Basic and Applied Sciences*, 9(1), 180-204. <https://www.tandfonline.com/doi/full/10.1080/2314808X.2022.2050115> <https://doi.org/10.1080/2314808X.2022.2050115>
36. Abdullahi, M., Uzairu, A., Shallangwa, G. A., Mamza, P. A. & Ibrahim, M. T. (2022). 2D-QSAR, 3D-QSAR, molecular docking and ADMET prediction studies of some novel 2-((1H-indol-3-yl) thio)-N-phenyl-acetamide derivatives as anti-influenza A virus. *Egyptian Journal of Basic and Applied Sciences*, 9(1), 510-532. <https://doi.org/10.1080/2314808X.2022.2108592>
37. Ameji, J. P., Uzairu, A., Shallangwa, G. A. & Uba, S. (2023). Obstructing Salmonella typhi's virulence in eukaryotic cells through design of its SipB protein antagonists. *Journal of Taibah University Medical Sciences*, 18(4), 726. <https://doi.org/10.1016/j.jtumed.2022.12.010>
38. Adawara, S. N., Shallangwa, G. A., Mamza, P. A. & Abdulkadir, I. (2022). Chemoinformatic design and profiling of some derivatives of 1, 2, 4-oxadiazole as potential dengue virus NS-5 inhibitors. *Bulletin of the National Research Centre*, 46(1), 65. <https://link.springer.com/article/10.1186/s42269-022-00755-7>
39. Adawara, S. N., Shallangwa, G. A., Mamza, P. A. & Abdulkadir, I. (2022). Computer-aided drug design and ADMET of novel potent dengue virus NS-5 inhibitors. *Chemistry Africa*, 5(4), 855-869. <https://link.springer.com/article/10.1007/s42250-022-00361-0>
40. Abdulrahman, M. D., Bradosty, S. W., Hamad, S. W., Ibrahim, M. T., Lema, A. A., Sunusi, N., ... & Bussmann, R. W. (2022). Traditional Methods for Treatment and Management of Measles in Northern Nigeria: Medicinal plants and their molecular docking. *Ethnobotany Research and Applications*, 23, 1-18. <https://ethnobotanyjournal.org/era/index.php/era/article/view/3595>
41. Umar, A. B. & Uzairu, A. (2022). Exploration of Anticancer Potential of Novel Pyrrolo[2,3-b]pyridine Derivatives Targeting V600E-BRAF Kinase: Molecular Docking, Pharmacokinetic and DFT Studies. *Advanced Journal of Chemistry A*, 5(4), 271-286.
42. Philip, J., Uzairu, A., Shallangwa, G., & Uba, S. (2023). Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi. *Current Chemistry Letters*, 12(1), 1-16. DOI: [10.5267/j.ccl.2022.10.002](https://doi.org/10.5267/j.ccl.2022.10.002)
43. Ibrahim, M. M., Uzairu, A., Ibrahim, M. T. & Umar, A. B. (2023). Modelling PIP4K2A inhibitory activity of 1, 7-naphthyridine analogues using machine learning and molecular docking studies. *RSC advances*, 13(6), 3402-3415. <https://doi.org/10.1039/D2RA07382J>
44. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S. & Umar, A. B. (2023). 2D and 3D-QSAR Modeling of 1H-Pyrazole Derivatives as EGFR Inhibitors: Molecular Docking, and Pharmacokinetic Profiling. *Chemistry Africa*, 1-18. <https://link.springer.com/article/10.1007/s42250-023-00592-9>
45. Akinola, L. K., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2023). Development and Validation of Predictive QSAR Models for Estrogenic Activities of Hydroxylated Polychlorinated Biphenyls. *Environmental Toxicology and Chemistry*. <https://setac.onlinelibrary.wiley.com/doi/abs/10.1002/etc.5566>
46. Nulamuga, B., Uzairu, A., Babalola, I. T., Ibrahim, M. T. & Umar, A. B. (2023). In silico analysis of noscapine compounds as anti-tumor agents targeting the tubulin receptor. *Journal of Taibah University Medical Sciences*, 18(1), 32. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643549/>
47. Abduljelil, A., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2023). Virtual screening, molecular docking simulation and ADMET prediction of some selected natural products as potential inhibitors of NLRP3 inflammasomes as drug candidates for Alzheimer disease. *Biocatalysis and Agricultural Biotechnology*, 102615. <https://www.sciencedirect.com/science/article/abs/pii/S1878818123000166>
48. Umar, A. B., & Uzairu, A. (2023). Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential V600E-BRAF kinase inhibitors. *Journal of Taibah University Medical Sciences* (forthcoming).
49. Ameji, P. J., Uzairu, A., Shallangwa, G. A. & Uba, S. (2023). Molecular docking simulation, drug-likeness assessment, and pharmacokinetic study of some cephalosporin analogues against a penicillin-binding protein of Salmonella typhimurium. *The Journal of Antibiotics*, 1-14. <https://www.nature.com/articles/s41429-023-00598-y>
50. Oyegoke, T., Dabai, F. N., Waziri, S. M., Uzairu, A. & Jibril, B. Y. (2023). Computational study of propene selectivity and yield in the dehydrogenation of propane via process simulation approach. *Physical Sciences Reviews*. <https://doi.org/10.1515/psr-2022-0242>
51. Ejeh, S., Uzairu, A., Shallangwa, G. A., Abechi, S. E., Ibrahim, M. T., Ramu, R. & Al-Ghorbani, M. (2023). Chemical bioinformatics study of Nonadec-7-ene-4-carboxylic acid derivatives via molecular docking, and molecular dynamic simulations to identify novel lead inhibitors of hepatitis c virus NS3/4a

- Protease. Scientific African, e01591. <https://doi.org/10.1016/j.sciaf.2023.e01591>
52. Abdullahi, M., Uzairu, A., Shallangwa, G. A., Mamza, P. A. & Ibrahim, M. T. (2023). Computational modelling of some phenolic diterpenoid compounds as anti-influenza A virus agents. Scientific African, 19, e01462. <https://doi.org/10.1016/j.sciaf.2022.e01462>
 53. Ibrahim, M. T. & Uzairu, A. (2023). 2D-QSAR, molecular docking, drug-likeness, and ADMET/pharmacokinetic predictions of some non-small cell lung cancer therapeutic agents. Journal of Taibah University Medical Sciences, 18(2), 295. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926115/>
 54. Ajala, A., Uzairu, A., Shallangwa, G. A. & Abechi, S. E. (2023). QSAR, simulation techniques, and ADMET/pharmacokinetics assessment of a set of compounds that target MAO-B as anti-Alzheimer agent. Future Journal of Pharmaceutical Sciences, 9(1), 1-20. <https://fjps.springeropen.com/articles/10.1186/s43094-022-00452-2>
 55. Ameji, J. P., Uzairu, A., Shallangwa, G. A. & Uba, S. (2023). Design, pharmacokinetic profiling, and assessment of kinetic and thermodynamic stability of novel anti-Salmonella typhi imidazole analogues. Bulletin of the National Research Centre, 47(1), 1-12. <https://bnrc.springeropen.com/articles/10.1186/s42269-023-00983-5>
 56. Umar, A. B. & Uzairu, A. (2023). Molecular modeling strategy to design novel anticancer agents against UACC-62 and UACC-257 melanoma cell lines. Egyptian Journal of Basic and Applied Sciences, 10(1), 157-173. <https://www.tandfonline.com/doi/full/10.1080/2314808X.2022.2161037>

Patent awarded

Awardee(s)	Patent name	Country awarded	Department	Faculty
Suleiman MUKTARI (Nigeria), Anton Kuzmin, Vyacheslav V. Kuznetsov (Russia)	Patent 2786104 Polyimide composition for the production of Machine building products (December, 2022)	Russia	Polymer and Textile Engineering	Engineering

Grants won

Principal Investigator	Title of Grant	Co-Investigators	Department	Faculty	Amount
TETFund National Research Fund (NRF) 2021 Grant Cycle					
Dalhat Khalid Sani	Alternative to Care for the terminally ill Patients in Northwestern Nigeria	A. S. Kombo, H. M. Sani, Y. Umar, A. M. Ladan, A. M. Sani, I. A. Haliru	Nursing	Allied Health Sciences	₦ 12,437,500.00
Bilal SABI'U	Development of Drilling Fluid from Indegenous Bentonite for High -Temperature High Pressure (HTHP) Reservoir Conditions	I. A. Mohammed - Dabo, Abdulhamid Hamza, Ismail Yusuf Abubakar, Tukur Muhammad, Bala Usman, Bello Ayobami	Chemical Engineering	Engineering	₦ 37,850,000.00
Abdulrasheed Ibrahim	Application of Implementation of Science to Develop and Evaluate a Systems Strengthenin g Intervention for Paediatric Acute Burn Resuscitation in North - West Nigeria	M. L. Abubakar, Ganiyu Oseni, P. A. Nazish, Rebecca DeBoer, Farouk Mohammed, Sufiyan Muawiyah Babale, M. M. Dauda, Saidu Yusuf Yakubu	Surgery	Clinical Sciences	₦ 12,500,000.00
Iliyasu IBRAHIM	A Novel Hydroxyapatite - Strontium doped Chitosan/Polyactic Acid Hydrogel for the regeneration of load bearing Osteoporotic bone defects	David O. Obada, Muhammad Dauda, Mohammed K. Yakubu, Laminu S. Kuburi, Emmanuel Okafor, B abalola A. Ibisola, Ya'u Z. Lawal, Emmanuel Gaba, Folashade F. Ajimohun	Mechanical Engineering	Engineering	₦ 20,908,589.71

Abdulazeez Yusuf ATTA	Development and Optimization of a pilot plant for the selective recovery of gold from gold ore deposit using novel Alpha - Cyclodextrin Technique	Usman Abubakar, Shehu Suleiman Magaji, Tanimu Gazali, Baba Jibril El-Yakubu	Chemical Engineering	Engineering	₦ 23,625,000 .00
Yahaya Abbas ALIYU	Monitoring the elemental components of PM2.5 and atmospheric Palynomorphs around Lekki, Lagos, Nigeria	Rose Anthony Alani, Opeyemi Olusegun Ayejuyo, Olusola Helen Adekanmbi, Godwin Chigaeke Ezech, Salimon Kolawole Muyiolu, Chukwuma John Okolie	Geomatics	Environmental Design	₦ 20,505,125 .00
Abdulsalam MOHAMMED	Direct conversion of waste into a useful Bio - Absorbent as a measure to prevent Environmental hazard	Nurudeen Salahudeen, Moshudi Isiaka, Muhammad Mujahid Muhammad, Aminu Saleh, Ibrahim B. Dalha, Aliyu O. Abede	Agricultural and Bio - Resources Engineering	Engineering	₦ 22,000,000 .00
Muhammad Khalid OTHMAN	Improving the Quality of Rice Produced in Nigeria: Design and development of an Artificial based Rice De-Stoning Machine	A. O. Lawal, Luqman Durojaiye, T. O. Olarewaju, Baba Dahiru	National Agricultural Extension and Research Liaison Services	NAERLS	₦ 14,000,000 .00
Mohammed ABDULLAHI	Development of an intelligent and secured gates monitoring using vehicle's Digital Image processing	Armand F. Donfack Kana, Mustapha Bagiwa Aminu, Ime Jariath Umoh, Sahalu B. Junaidu, Afolayan A. Obiniyi, Fatima Binta Abdullahi, Bashir H. Sani, Jeffrey Agushaka Ovre, Ibrahim Iliyasu	Computer Science	Physical Sciences	₦ 26,000,000 .00
Fadlullah Olayiwola ISSA	Adaptation of conventional septic tank to Bio -Digester for Sustainable energy generation and viable economy for household use in Nigeria	A. O. Lawal, Olarewaju Taofiq, Akeem Wahab, Eunice Godiya	National Agricultural Extension and Research Liaison Services	NAERLS	₦ 19,990,150 .00

Abdulkareem ABUBAKAR	Novel technique of enriching Fructose Syrup from Sweet Sorghum using Ionic Liquid -Based Separation	Alewo Opuada Ameh, Suleiman Mohammed Shuwa, Suleiman Yunusa	Chemical Engineering	Engineering	₦ 35,825,000 .00
Muhammad Mujahid MUHAMMAD	Novel Hybrid Smart Solar -Thermal Drying System as a Measure for preventing loss of Agro -produce	Muhammad Bashir Abdulrazaq, Daniel. I. Onwude, Mohammed Abdulsalam, Ibrahim B. Dalha, Al-Amin D. Bello	Water Resources and Environmental Engine ering	Engineering	₦ 25,000,000 .00
Global Shapers Community/Ilorin Climate Action Challenge 2022					
Abdulkadir Ibrahim OBA	Integrating Climate Change and Smart Agriculture Contents into Nigerian School Curriculum	Hussein Ahmed Abdullahi	Vocation and Technical Education	Education	\$300.00
USDA -NIFA -AFRI -009003 Grant					
Ramatu Enehezeyi ALIYU (PI Nigeria)	Mining drought stress resilience at an early vegetative stage in cowpea (<i>Vigna unguiculata</i> L. Walp)	-----	Botany	Life Sciences	\$799,949.00

Grants, Fellowships and Funding Opportunities . . .

TWAS

The TWAS-CAS Young Scientists Award is honouring developing world researchers with achievements in mathematics and artificial intelligence! Nominate an accomplished candidate today:

<https://twas.org/opportunity/twas-cas-young-scientists-award-frontier-science>.

Africans are eligible; age limit-45 years!

NIH FUNDING

AHRQ Mentored Research Scientist Career Development award (K01)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-255.html>

Nov. 09, 2025

Advancing Methods for Safe, Noninvasive, Real Time assessment of Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PAR-22-236.html>

Nov. 16, 2024

Advancing Methods for Safe Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PAR-22-237.html>

Nov. 05, 2024

NIAID Research Opportunities for New and “At-Risk” Investigators to promote workforce Diversity (R01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PAR-22-241.html>

Sept. 07, 2025

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-039.html>

Sept. 12, 2024

Diversity Center for Genome Research (U54 Clinical Trials Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-026.html>

June 24, 2024

Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-027.html>

June 24, 2024

Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCH) UT1, UT2 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-031.html>

see announcement

Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCH) (U43/U44 - Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-032.html>

[Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome \(INCLUDE\) Clinical Research Short Course \(R25 Independent Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-195.html>

[NLM Research Grants in Biomedical Informatics and Data Science \(R01 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-034.html>

January 07, 2026

[Advancing Adolescent Tobacco Cessation Intervention Research \(R34 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-042.html>

Oct. 16, 2023

[Advancing Adolescent Tobacco Cessation Intervention Research \(R01 Clinical Trial Required\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-043.html>

Oct. 16, 2023

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH and Cancer (R01 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-056.html>

Dec. 15, 2023

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-057.html>

Dec. 15, 2023

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-061.html>

Nov. 14, 2024

[NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations \(R34 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-062.html>

Nov. 14, 2024

[Human Islet Research Network \(HIRN\) Pancreas Knowledgebase Program \(PanKbase\) \(U24 - Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-018.html>

March 31, 2023

[BRAIN Initiative Cell Atlas Network \(BICAN\): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases \(R01 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-292.html>

Feb. 01, 2024

[Development of Animal Models and Related Biological Materials for Down Syndrome Research \(R24 Clinical Trials Not-Allowed\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-247.html>

May 25, 2025

Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-253.html>

Not applicable

Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture Using Agriculturally Important Domestic Animal Species (R01)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-031.html>

Multiple dates, see announcement

Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-002.html>

March 29, 2023

Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-005.html>

see announcement

The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-028.html>

Nov. 22, 2024

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-021.html>

Multiple dates, see announcement

NCMRR Early Career Research Award (R03 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-029.html>

Multiple dates, see announcement

Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html>

Aug. 07, 2025

Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-039.html>

Not applicable

HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-248.html>

Sept. 07, 2025

Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-252.html>

Sept. 07, 2025

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-032.html>

Sept. 05, 2025

Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R24 Clinical Trials Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-039.html>

May 25, 2025

Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-040.html>

July 05, 2025

Occupational Safety and Health Education and Research Centers (T42)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OH-23-003.html>

Nov. 22, 2027

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-044.html>

Application during the submission process by the due date

Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-033.html>

March 14, 2025

Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-041.html>

July 28, 2025

Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-003.html>

Not applicable

Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-004.html>

Not applicable

Pediatric Critical Care and Trauma Scientist Development Program (K12 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-001.html>

March 29, 2023

HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-069.html>

see announcement

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-046.html>

Jan. 07, 2026

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-047.html>

Jan. 07, 2026

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-023.html>

see announcement

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-024.html>

see announcement

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-025.html>

see announcement

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-026.html>

see announcement

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-24-022.html>

Multiple dates, see announcement

Cooperative Centers on Human Immunology (U19 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-069.html>

April 07, 2023

[Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders \(R61/R33 - Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-002.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-002.html>

March 23, 2023

[Environmental Health Sciences Core Centers \(EHSCC\) \(P30 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-010.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-010.html>

see announcement

[Pragmatic Trials across the Cancer Control Continuum \(UG3/UH3 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-22-256.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-256.html>

Nov. 17, 2025

[Ancillary Studies to Ongoing Clinical Projects \(R01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-025.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-025.html>

Multiple dates, see announcement

[Ancillary Studies to Ongoing Clinical Projects \(R21 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-026.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-026.html>

Multiple dates, see announcement

[Leading Equity and Diversity in the Medical Scientist Training Program \(LEAD MSTP\)\(T32\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-030.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-030.html>

Jan. 27, 2025

[Mechanistic links between diet, lipid metabolism, and tumor growth and progression \(U01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-051.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-051.html>

Oct. 23, 2025

[Mechanistic links between diet, lipid metabolism, and tumor growth and progression \(U01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-052.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-052.html>

Oct. 23, 2025

[Research Infrastructure Development for Interdisciplinary Aging Studies \(R61/R33 - Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-053.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-053.html>

Dec. 02, 2025

[Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies \(R33 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-054.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-054.html>

Dec. 02, 2025

[NIAID Resource-Related Research Projects \(R24 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-065.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-065.html>

Jan. 07, 2026

[International Centers of Excellence for Malaria Research \(U19 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-067.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-067.html>

May, 04, 2023

[Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research \(R21 - Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-006.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-006.html>

March 29, 2023

[Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders \(R21 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-036.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-036.html>

Multiple dates, see announcement

[Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities \(U01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-037.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-037.html>

Multiple dates, see announcement

[NIA Multi-site Clinical Trial Implementation Grant \(R01 Clinical Trial Required\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-057.html>

Jan. 07, 2026

[FDA Support for Conferences and Scientific Meetings \(R13 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-072.html>

Multiple dates, see announcement

[Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research \(R61 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-002.html>

Multiple dates, see announcement

[Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research \(R33 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-003.html>

Multiple dates, see announcement

[Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research \(R61 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-004.html>

Multiple dates, see announcement

[Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research \(R33 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-005.html>

Multiple dates, see announcement

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(R01 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-006.html>

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(U01 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-007.html>

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(U54 Clinical Trials Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-008.html>

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(P01 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-009.html>

Not applicable

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(P50 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-010.html>

Not applicable

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(U2C Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-011.html>

Not applicable

[Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research \(U2C Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-017.html>

March 31, 2023

[Fostering Research With Additional Resources and Development \(FORWARD\) Urology Centers \(P20 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-027.html>

see announcement

[Cooperative Agreement to Support Regulatory Research Related to the 2022 Prescription Drug User Fee Act and Biosimilar User Fee Act \(U19\) Clinical Trials Not Allowed.](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-023.html>

March 13, 2023

[Opportunities for Advancing Limb Regeneration Research \(R01 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-004.html>

July 27, 2023

[NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 \(NCI Omnibus\) \(R03 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-058.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-058.html>

Multiple date, see announcement

[Development of Animal Models and Related Biological Materials for Down Syndrome Research \(R21 Clinical Trials Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-067.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-067.html>

Jan. 07, 2026

[NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds \(K26 - Independent Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-012.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-012.html>

see announcement

[Clinical Studies of Mental Illness \(Collaborative R01\) \(Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-050.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-050.html>

Jan. 07, 2026

[Co-infection and Cancer \(R01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-055.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-055.html>

Nov. 05, 2025

[Co-infection and Cancer \(R21 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-056.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-056.html>

Nov. 16, 2025

[National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 \(P01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-059.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-059.html>

May 07, 2026

[Interorgan Communication in Aging \(U01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-005.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-005.html>

June 01, 2023

[Mechanisms and Targets at the Intersection of HIV and Substance Use \(R01 Clinical Trials Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-013.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-013.html>

Aug. 09, 2023

[Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development \(U01\) Clinical Trial Optional](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-006.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-006.html>

Feb. 22, 2023

[HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research \(K99/R00 Independent Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-022.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-022.html>

March 11, 2025

[HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research \(Independent Basic Experimental Studies with Humans Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-023.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-023.html>

March 11, 2025

[HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity \(K99/R00 Independent Basic Experimental Studies with Humans Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-024.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-024.html>

March 11, 2025

[HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity \(K99/R00 Independent Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-025.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-025.html>

March 11, 2025

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Independent Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-003.html>

April 17, 2023

Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-063.html>

May 28, 2025

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-075.html>

Multiple dates, see announcement

Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-078.html>

May 08, 2023

Biomedical Data Repository (U24 - Clinical Trials Not Allowed)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-079.html>

May 08, 2023

Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-081.html>

Multiple dates, see announcement

Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-083.html>

Jan. 25, 2025

Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-070.html>

May 19, 2023

Autoimmunity Centers of Excellence, Clinical Research Program (UM1 Clinical Trial Required)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-071.html>

May 19, 2023

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-014.html>

Nov. 17, 2023

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-015.html>

Nov. 17, 2023

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html>

Nov. 17, 2023

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-017.html>

Nov. 17, 2023

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-023.html>

Multiple dates, see announcement

BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-335.html>

Multiple dates, see announcement

[Enhancing the Use of the All of Us Research Programs Data \(R21 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-PM-23-001.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-PM-23-001.html>

March 01, 2023

[Small Grants to Enhance the Use of the All of Us Research Programs Data \(R03 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-PM-23-002.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-PM-23-002.html>

March 01, 2023

[HEAL Commercialization Readiness Pilot \(CRP\) Program: Embedded Entrepreneurs for Small Businesses in Pain Management \(SB1 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-069.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-069.html>

Sept. 05, 2025

[Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development \(R01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-091.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-091.html>

Multiple dates, see announcement

[Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-092.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-092.html>

Multiple dates, see announcement

[Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-093.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-093.html>

Multiple dates, see announcement

[Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents \(R01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-094.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-094.html>

Multiple dates, see announcement

[Innovative Mental Health Services Research Not Involving Clinical Trials \(R01 Clinical Trials Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-095.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-095.html>

Multiple dates, see announcement

[Laboratories to Optimize Digital Health \(R01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-096.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-096.html>

Multiple dates, see announcement

[Mood and Psychosis Symptoms during the Menopause Transition \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-097.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-097.html>

Multiple dates, see announcement

[Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus \(R01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-028.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-028.html>

Feb. 29, 2024

[BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development \(UG3/UH3 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-003.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-003.html>

Oct. 13, 2023

[Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID \(U24 - Clinical Trials Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-002.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-002.html>

March 17, 2023

[Archiving and Documenting Child Health and Human Development Data Sets \(R03 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-22-261.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-22-261.html>

Multiple dates, see announcement

[Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes \(R34 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-060.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-060.html>

January, 09, 2026

[Innovations to Optimize HIV Prevention and Care Continuum Outcomes \(R21 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-061.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-061.html>

January 09, 2026

[Innovations to Optimize HIV Prevention and Care Continuum Outcomes \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-062.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-062.html>

Jan. 09, 2026

[NIDA Program Project Grant Applications \(P01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-064.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-064.html>

January 07, 2026

[In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability \(R01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-074.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-074.html>

Multiple dates, see announcement

[NIDA Research Center of Excellence Grant Program \(P50 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-076.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-076.html>

Multiple dates, see announcement

[Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment \(U01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-082.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-082.html>

Feb. 21, 2025

[Investigator Initiated Extended Clinical Trial \(R01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-084.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-084.html>

Multiple dates, see announcement

[Novel Assays to Address Translational Gaps in Treatment Development \(UG3/UH3 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-087.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-087.html>

Multiple dates, see announcement

[Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders \(R21 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-101.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-101.html>

Multiple dates, see announcement

[Mood and Psychosis Symptoms during the Menopause Transition \(R21 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-102.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-102.html>

Multiple dates, see announcement

[Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes \(R34 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-103.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-103.html>

Multiple dates, see announcement

[Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents \(R34 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-104.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-104.html>

Multiple dates, see announcement

[Innovative Pilot Mental Health Services Research Not Involving Clinical Trials \(R34 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-105.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-105.html>

Multiple dates, see announcement

[Alzheimer's Disease Research Centers \(P30 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-001.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-001.html>

Sept. 26, 2025

[Renewal of the Interventions Testing Program \(U01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-002.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-002.html>

June 19, 2023

[Interventions Testing Program \(ITP\) Data Coordinating Center \(U24 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-003.html>

June 19, 2023

[Planning for the TMD Collaborative for IMproving PATient-Centered Translational Research \(TMD IMPACT\) \(R34 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-014.html>

April 14, 2023

[Accelerating Data and Metadata Standards in the Environmental Health Sciences \(R24 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-002.html>

May 10, 2023

[Pediatric Heart Network Clinical Research Centers \(UM1 Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-001.html>

May 12, 2023

[Limited Competition: Pediatric Heart Network for the Data Coordinating Center \(U24 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-002.html>

May 12, 2023

[Amyotrophic Lateral Sclerosis \(ALS\) Intermediate Patient Population Expanded Access \(U01 Clinical Trial Required\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-012.html>

March 23, 2023

[Animal and Biological Material Resource Centers \(P40\) \(Clinical Trials Not-Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-001.html>

Multiple dates, see announcement

[Ruth L. Kirschstein National Research Service Award \(NRSA\) Short-Term Institutional Research Training Grant \(Parent T35\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-080.html>

Multiple dates, see announcement

[Time-Sensitive Research Opportunities in Environmental Health Sciences \(R21 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-004.html>

Multiple dates, see announcement

[Pediatric Device Consortia Grants Program \(P50\) Clinical Trials Optional](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-024.html>

March 29, 2023

[AHRQ Small Research Projects to Advance the Science of Primary Care \(R03\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-115.html>

June 16, 2023

[Development and Maintenance of Human and Animal Food Rapid Response Teams \(U2F\) Clinical Trials Not Allowed](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-019.html>

April 14, 2023

[Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs \(U2F\) Clinical Trials Not Allowed](#)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-027.html>

April 14, 2023

[Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models \(R13 Clinical Trial Not Allowed\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PAR-22-262.html>

Jan. 07, 2024

[Collaborative Program Grant for Multidisciplinary Teams \(RM1 - Clinical Trial Optional\)](#)

<http://grants.nih.gov/grants/guide/pa-files/PAR-23-077.html>

Multiple dates, see announcement

[NIMHD Exploratory/Developmental Research Grant Program \(R21 - Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-111.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-111.html>

May 07, 2026

[Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities \(R01 - Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-112.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-112.html>

Jan. 07, 2026

[Team Science Approaches Integrating Experimental and Computational Brain Aging Models \(R21/R33 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-018.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-018.html>

Sept. 22, 2023

[Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation \(R21 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-23-001.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-23-001.html>

Oct. 02, 2023

[FDA OMMHE Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity \(REACH\) \(U01\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-010.html)

[Clinical Trials Optional](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-010.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-010.html>

April 06, 2-23

[Technologies for Improving Minority Health and Eliminating Health Disparities \(R41/R42- Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-002.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-002.html>

Sept. 06, 2023

[Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities \(R43/R44 - Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-003.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-003.html>

Sept. 06, 2023

[Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program \(X01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-035.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-035.html>

March 21, 2023

[IDeA Networks of Biomedical Research Excellence \(INBRE\) \(P20 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/pa-files/PA-23-100.html)

<http://grants.nih.gov/grants/guide/pa-files/PA-23-100.html>

May 22, 2025

[Research Coordinating Center on the Exposome and Alzheimer's Disease \(AD\) and AD-Related Dementias \(ADRD\): Elucidating the Role of Social and Behavioral Determinants of Health in AD/ADRD Etiology and Disparities \(U24 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-011.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-011.html>

Sept. 27, 2023

[Comparative Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging-Related Outcomes, and Prospects for Translation \(R01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-019.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-019.html>

Sept. 27, 2023

[Networking/Infrastructure Project for Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging Related Outcomes, and Prospects for Translation \(R61/R33 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-020.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-020.html>

Sept. 27, 2023

[Consortium for Food Allergy Research: Clinical Research Center \(U01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-076.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-076.html>

June 09, 2023

[Consortium for Food Allergy Research: Leadership Center \(UM1 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-077.html)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-077.html>

June 09, 2023

[Sexually Transmitted Infections \(STI\) Cooperative Research Centers \(CRC\): Vaccine Development \(U01 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-008.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-008.html>

June 14, 2023

[Education Activities for Responsible Analyses of Complex, Large-Scale Data \(R25- Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-027.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-027.html>

February 08, 2024

[Accelerating the Pace of Drug Abuse Research Using Existing Data \(R21 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-037.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-037.html>

Nov.15, 2024

[Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork \(RADIANT\) Specialized Study Centers \(U54 - Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-511.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-511.html>

June 07, 2023

[Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-006.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-006.html>

May 04, 2023

[Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care \(R01 Clinical Trial Required\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-007.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-007.html>

Not applicable

[Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection \(R01 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-008.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-23-008.html>

Not applicable

[Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials \(U19 Clinical Trial Optional\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-001.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-001.html>

June 01, 2023

[Advancing Gender Inclusive Excellence \(AGIE\) Coordinating Center \(U24 Clinical Trial Not Allowed\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-004.html)
<http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-004.html>

Jan. 31, 2024

ERC FUNDING AND FELLOWSHIPS

<https://erc.europa.eu/>

Public funding linked to ERC projects

1. Jobs in ERC teams: Recipients of ERC grants can use their funding to recruit other researchers and team members for their project. On average, each team has 4-5 members. Since its inception, ERC funding has helped create jobs for thousands of researchers.
2. Visiting Research Fellowships: A number of European countries fund research visits to established ERC projects in order to develop researchers' potential before they apply for their first ERC grant.
3. International Arrangement funding: International agreements with funding agencies and science ministries in China, South Africa, the United States and some other countries support early-career researchers to temporarily join ERC teams in Europe.
4. Mentoring Initiative: the mentoring initiative will boost existing support programmes for ERC applicants by helping to identify international experts to provide coaching and advice.

Jobs in ERC teams

Apply on the [EURAXESSportal](#), using the [European Research Council \(ERC\) filter](#). [Jobs in ERC-funded projects might also be published without the ERC tag and can be advertised on other websites and in journals.](#)

Apply to the Principal Investigator (PI) at the institution hosting the project — the Host Institution — using the contact details in the job advertisement.

To relocate to another country to pursue your research career, your [local or regional EURAXESS centre can also provide advice on matters such as visa formalities, work permits, accommodation and social security for countries in Europe.](#)

Visiting Research Fellowships

Visiting Research Fellowship placements are available via national or regional funding agencies. Funding covers all costs of the research visit including salary, travel and reasonable subsistence costs. However, you must apply for an ERC grant after the visit within a time specified in your funding agreement.

Conditions vary according to each national or regional funding agency's requirements and the positions available in ERC research teams.

Current Visiting Research Fellowship programmes in place:

- Bucharest (Romania), Politehnica University of Bucharest (UPB) [More Information](#)
- Croatia, with the Croatian Science Foundation (HRZZ) [More information](#)
- Estonia, with the Estonia Research Council (ETag) [More information](#)
- Flanders (Belgium), with the Research Foundation Flanders (FWO) [More information](#)
- Georgia, with the Shota Rustaveli National Science Foundation (SRNSFG) [More information](#)
- Italy, National Research Council (CNR)
- Republic of Serbia, Ministry of Education, Science and Technological Development of the Republic of Serbia (MoESTD) [More information](#)
- Slovak Republic, with the Slovak Academy of Sciences (SAS) & Pavol Jozef Safarik University in Kosice (UPJS).
- Slovenia, with the Slovenian Research Agency (ARRS) [More information](#)
- National and/or regional authorities who want to set up a programme can consult the [guidelines. New programmes are added to this scheme after endorsement by the ERC Scientific Council.](#)

- Placements in ERC-funded projects are available following ERC calls for Principal Investigators (PIs) to express an interest in hosting visiting research fellows. The ERC then sends each funding agency a list of interested PIs or teams, with a description of their projects.
- Find out whether you are eligible for one of the national funding programmes.
- Apply directly to a funding agency for a programme for which you are eligible.
- If you are accepted, the agency will tell you which placements are available.
- You can then contact the PI offering a placement to express an interest in working in the research team.
- When you and the PI have agreed on the details, the Host Institution will send a 'letter of intent' or 'support letter' on behalf of the PI to your funding agency to apply for funding
- Your funding agency can then fund you to work on the project.

Send any general questions about the implementation of these programmes to erc-visiting-fellowship-programmes@ec.europa.eu. [Send specific questions about how to apply or your application to your local funding agency.](#)

The first call to PIs for expressions of interest was launched on 1 September 2016. Further calls are expected to take place every year in June.

Conditions vary according to funding agency's requirements and the positions available in ERC research teams. Currently the following Implementing Arrangements are in place:

- Argentina
 - Signed in March 2015 with the Ministry of Science, Technology and Productive Innovation
- Read more: [agreement](#) [ES|EN, press highlight](#), [For the interested CONICET-funded scientists, see more here](#)

- Australia
 - Signed in February 2019 with the Australian Research Council (ARC)
- Read more: [agreement](#), [press release](#)
- Signed in October 2018 with the National Health and Medical Research Council (NHMRC)

Read more: [agreement](#), [press release](#)

- Brazil
- Signed in October 2016 with the Brazilian National Council of the State funding agencies (CONFAP) [press highlight](#), [leaflet](#)
- Canada
- Signed in October 2016 with the Tri-agency Institutional Programs Secretariat
- Read more: [agreement](#), [press highlight](#) [EN|FR](#)

- China
- Signed in June 2015 with the National Natural Science Foundation (NSFC)
- Read more: [agreement](#) [ZH|EN, press highlight](#)

For interested NSFC-funded scientists, see more [here](#)

- India
- Signed in October 2020 with the Indian Council of Social Science Research (ICSSR)
- Read more: [agreement](#), [press highlight](#)
- Signed in October 2017 with the Scientific Engineering Research Board (SERB)

Read more: [agreement](#), [press highlight](#)

- Japan
- Signed in November 2020 with the Agency for Medical Research and Development (AMED) of Japan
- Read more: [agreement](#)[EN](#), [press release](#)
- Signed in October 2018 with the Japan Science and Technology Agency (JST)
- Read more: [agreement](#), [press release](#)
- Signed in May 2015 with the Japan Society for the Promotion of Science (JSPS)
- Read more: agreement [EN](#), [press release](#)
- For the interested JSPS-fellows, see more [here](#)

- Korea
- Signed in November 2013 with the Ministry of Science, ICT and Future Planning
- Read more: [agreement](#), [press highlight](#)
-
- Mexico
- Signed in November 2015 with the Mexican National Council of Science and Technology (Conacyt)
- Read more: agreement [ES](#)[EN](#), [press highlight](#)

- Singapore
- Signed in October 2019 with the National Research Foundation Singapore (NRF)
- Read more [agreement](#), [press release](#)

- South Africa
- Signed in October 2015 with the National Research Foundation (NRF)
- Read more: agreement [EN](#)

- Thailand
- Signed in September 2022 with the Programme Management Unit for Human Resources & Institutional Development, Research and Innovation (PMU-B)
- Read more: [agreement](#), [press highlight](#)
-
- United States
- Signed in July 2012 with the National Science Foundation (NSF)
- Read more: [agreement](#), [press release](#)

ERC [calls for Principal Investigators \(PIs\) to express an interest in hosting early-career scientists supported by non-European funding agencies.](#)

ERC Mentoring Initiative

ERC Mentoring Initiative is available via local offices in the EU Member States and Associated Countries whose mentoring requests were accepted by the ERC.

Currently, the following ERC Mentoring Initiatives are in place:

- Cyprus - Research and Innovation Foundation (RIF)
- Czech Republic - Czech National Expert Group (NEG) for the ERC
- Estonia - Estonian Research Council (ETAg)
- Hungary - Hungarian Academy of Sciences (MTA)
- Italy - National Research Council (CNR)
- Malta - Malta Council for Science and Technology (MCST)
- Poland - National Centre for Research and Development (NCBR), National Science Centre (NCN) and the Foundation for Polish Science (FNP)
- Slovakia - Horizon National Office - Slovak Centre of Scientific and Technical Information (CVTI SR)
- Turkey - Scientific and Technological Research Council of Turkey (TÜBİTAK)

National and/or regional offices who want to benefit from this initiative can consult the [guidelines](#).

The local offices in charge of the national/regional support programme should coordinate their participation in the ERC Mentoring Initiative with the [National Contact Points; National Contact Points will serve as the primary contact to the ERC concerning the local offices.](#)

•The proposal of maximum two pages should include:

- General information on the office and on the type of support provided to potential ERC applicants;
- Motivation for participating in the ERC Mentoring Initiative.

The deadline for the first round of expression of interest for national/regional offices to participate in the initiative was 23 April 2021. A new call for expression of interest will be announced here in the future. Interested national and/or regional offices will submit proposals to participate in the ERC Mentoring Initiative to their National Contact Point.

ERC-MENTORING-INITIATIVE@ec.europa.eu. Send any general questions about the implementation of these programmes to ERC-MENTORING-INITIATIVE@ec.europa.eu.

PIs preparing an ERC research proposal

Pis preparing an ERC proposal can send specific questions about how to get mentoring for their ERC application to their national/regional office.



©2023 Produced by the Research and Innovation Unit, Directorate of Academic Planning and Monitoring, Ahmadu Bello University

Editor-in-Chief: Professor Joy Joshua Maina, Deputy Director Research and Innovation, Directorate of Academic Planning and Monitoring, Ahmadu Bello University

Layout/Design: Ahmad Muktar, Directorate of University Advancement, ABU | Professor J. J. Maina



AHMADU BELLO UNIVERSITY,
ZARIA - NIGERIA
Est. 1962 | abu.edu.ng



NEWSLETTER

DIRECTORATE OF ACADEMIC PLANNING AND MONITORING
4th Floor, Senate Building, Samaru Main Campus, Zaria - Kaduna, Nigeria

All inquiries and correspondences
should be forwarded to:
research@abu.edu.ng